FRAGMIN 1 Indications

dalteparin sodium

(

Fragmin (Dalteparin Sodium Injection) is indicated for:

  • Thromboprophylaxis in conjunction with surgery
  • Treatment of acute deep venous thrombosis
  • Unstable coronary artery disease (UCAD), i.e., unstable angina and non-Q-wave myocardial infarction
  • Prevention of clotting in the extracorporeal system during hemodialysis and hemofiltration in connection with acute renal failure or chronic renal insufficiency
  • Extended treatment of symptomatic venous thromboembolism (VTE) to prevent recurrence of venous thromboembolism in patients with cancer
  • Reduction of deep vein thrombosis (DVT) in hospitalized patients with severely restricted mobility during acute illness. Decreased mortality due to thromboembolic events and complications has not been demonstrated

1.1 Pediatrics

Pediatrics (2 weeks – 18 years): Health Canada has not authorized an indication for pediatric use. There is limited safety and efficacy information on the use of dalteparin in pediatric patients (see Monitoring and Laboratory Tests, 7.1.3 Pediatrics, and Use in Pediatrics (2 weeks – 18 years)). 

1.2 Geriatrics

Geriatrics: Elderly patients may be at an increased risk for bleeding complications within the therapeutic dosage ranges. Careful clinical monitoring is advised (see Monitoring and Laboratory Tests and 7.1.4 Geriatrics).
 

)

Find FRAGMIN medical information:

Find FRAGMIN medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

FRAGMIN Quick Finder

Product Monograph
Download Product Monograph

Health Professional Information

1 Indications

Fragmin (Dalteparin Sodium Injection) is indicated for:

  • Thromboprophylaxis in conjunction with surgery
  • Treatment of acute deep venous thrombosis
  • Unstable coronary artery disease (UCAD), i.e., unstable angina and non-Q-wave myocardial infarction
  • Prevention of clotting in the extracorporeal system during hemodialysis and hemofiltration in connection with acute renal failure or chronic renal insufficiency
  • Extended treatment of symptomatic venous thromboembolism (VTE) to prevent recurrence of venous thromboembolism in patients with cancer
  • Reduction of deep vein thrombosis (DVT) in hospitalized patients with severely restricted mobility during acute illness. Decreased mortality due to thromboembolic events and complications has not been demonstrated

1.1 Pediatrics

Pediatrics (2 weeks – 18 years): Health Canada has not authorized an indication for pediatric use. There is limited safety and efficacy information on the use of dalteparin in pediatric patients (see Monitoring and Laboratory Tests, 7.1.3 Pediatrics, and Use in Pediatrics (2 weeks – 18 years)). 

1.2 Geriatrics

Geriatrics: Elderly patients may be at an increased risk for bleeding complications within the therapeutic dosage ranges. Careful clinical monitoring is advised (see Monitoring and Laboratory Tests and 7.1.4 Geriatrics).
 

Resources

Didn’t find what you were looking for? 

Contact us

Call 1-800-463-6001*

*Contact Medical Information. 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product: 1 866 723-7111.

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

Canada Vigilance Program 

You may also contact the Canada Vigilance Program directly to report adverse events or product quality concerns at 1-866-234-2345 or www.healthcanada.gc.ca/medeffect.